Scarica l'app Stockscreener
2.74
9.87%
-0.30
Dopo l'orario di chiusura:
2.90
0.16
+5.84%
Precedente Chiudi:
$3.04
Aprire:
$3.09
Volume 24 ore:
1.59M
Relative Volume:
0.82
Capitalizzazione di mercato:
$224.92M
Reddito:
$531.00K
Utile/perdita netta:
$-99.96M
Rapporto P/E:
-1.2501
EPS:
-2.1919
Flusso di cassa netto:
$-98.96M
1 W Prestazione:
-16.97%
1M Prestazione:
-35.53%
6M Prestazione:
-57.05%
1 anno Prestazione:
-66.59%
Intervallo 1D:
$2.74
$3.09
Intervallo di 1 settimana:
$2.74
$3.465
Portata 52W:
$2.74
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Nome
Lexeo Therapeutics Inc
Settore
Industria
Telefono
(212) 547-9879
Indirizzo
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
2.74 | 224.92M | 531.00K | -99.96M | -98.96M | -2.1919 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Raymond James | Strong Buy |
| 2025-11-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-10-15 | Iniziato | Guggenheim | Buy |
| 2025-07-31 | Iniziato | Oppenheimer | Outperform |
| 2024-06-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-06 | Iniziato | H.C. Wainwright | Buy |
| 2023-11-28 | Iniziato | Chardan Capital Markets | Buy |
| 2023-11-28 | Iniziato | JP Morgan | Overweight |
| 2023-11-28 | Iniziato | Leerink Partners | Outperform |
| 2023-11-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-11-28 | Iniziato | Stifel | Buy |
Mostra tutto
Lexeo Therapeutics Inc Borsa (LXEO) Ultime notizie
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference - GlobeNewswire Inc.
A healthcare conference fireside chat will stream live Oct. 20, featuring Lexeo Therapeutics. - Stock Titan
Stifel reiterates Buy rating on Lexeo Therapeutics stock at $17 By Investing.com - Investing.com South Africa
Stifel reiterates Buy rating on Lexeo Therapeutics stock at $17 - Investing.com
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS) - GlobeNewswire Inc.
Lexeo Therapeutics Finalizes Acquisition of Mantle Therapeutics in $8.3M Cash and Stock Deal - Kalkine Media
Form 8K Lexeo Therapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria
Lexeo Therapeutics completes acquisition of Mantle Therapeutics - Investing.com
Lexeo Therapeutics Reports Unregistered Equity Issuances Post-Merger - TipRanks
Lexeo Therapeutics completes acquisition of Mantle Therapeutics By Investing.com - Investing.com South Africa
Form 8K Lexeo Therapeutics Inc For: 29 September By Investing.com - Investing.com Canada
Lexeo Therapeutics (LXEO) medical chief acquires 2,714 shares through an employee plan - Stock Titan
Lexeo Therapeutics (LXEO) awards its COO an option covering 54,750 shares - Stock Titan
At $3.39 a share, Lexeo Therapeutics (LXEO) grants its CFO 54,750 stock options. - Stock Titan
Lexeo Therapeutics (LXEO) CEO acquires 2,306 shares through an employee plan and receives a stock option. - Stock Titan
A virtual heart-and-metabolism forum will include Lexeo on Sept. 30. - Stock Titan
Why is Lexeo Therapeutics stock gaining today? - Investing.com
Lexeo Therapeutics to Acquire Mantle Therapeutics for $8.3M Upfront, Up to $13M in Milestones - TradingView
Lexeo Therapeutics (NasdaqGM:LXEO) Stock Forecast & Analyst Predictions - Simply Wall Street
Lexeo Therapeutics, Inc. agreed to acquire Mantle Therapeutics Inc. for $21.3 million . - marketscreener.com
We're Not Very Worried About Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Rate - simplywall.st
Lexeo Therapeutics at Cantor conference: gene therapy push gains traction By Investing.com - Investing.com Nigeria
Lexeo Therapeutics at Cantor conference: gene therapy push gains traction By Investing.com - Investing.com Canada
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September - The Manila Times
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September - Yahoo Finance
Balyasny Asset Management L.P. Expands Stake in Lexeo Therapeuti - GuruFocus
Lexeo Therapeutics (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 3,345 Shares - MarketBeat
Louis Edward Tamayo Sells 4,117 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock - MarketBeat
Lexeo Therapeutics CFO Louis Edward Tamayo Sells 4,117 Shares to Settle RSU Tax Liabilities - Kalkine Media
Lexeo Therapeutics COO Jose Manuel Otero Sells Shares to Cover RSU Tax Liability - Kalkine Media
Lexeo Therapeutics CEO Richard Nolan Townsend Sells 3,345 Shares to Settle RSU Tax Liabilities - Kalkine Media
Lexeo Therapeutics (LXEO) CFO sells shares for RSU taxes - Stock Titan
Lexeo (NASDAQ: LXEO) CEO sale covers RSU tax bill, keeps 374K shares - Stock Titan
Lexeo Therapeutics (LXEO) COO sells 1,304 shares, retains 136K stake - Stock Titan
Lexeo (NASDAQ: LXEO) holder plans stock sale to cover tax bill - Stock Titan
Lexeo Therapeutics (LXEO) holder plans 1,304-share sale - Stock Titan
Lexeo Therapeutics (NASDAQ: LXEO) insider to sell 4,117 shares - Stock Titan
Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Lowered by Wall Street Zen - MarketBeat
Lexeo Therapeutics (LXEO): OrbiMed entities disclose combined 5% ownership stake - Stock Titan
Lexeo Therapeutics (LXEO): Paradigm BioCapital reports over 5% beneficial stake - Stock Titan
Balyasny Asset Management (LXEO) discloses 7.84M-share Lexeo Therapeutics stake capped at 9.99% - Stock Titan
Lexeo Therapeutics (LXEO): Affinity Asset Advisors reports 8.4% beneficial stake - Stock Titan
Hennion & Walsh Asset Management Inc. Invests $1.24 Million in Lexeo Therapeutics, Inc. $LXEO - MarketBeat
Lexeo Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Hits Estimates - marketbeat.com
META_TITLE_QUOTE - Yahoo Finance
Form 8K Lexeo Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Lexeo Therapeutics advances gene therapy and gains RMAT status - TipRanks
LXEO: Gene therapies for rare cardiac diseases advance with strong data, pipeline, and financial runway - TradingView
Form 8K Lexeo Therapeutics Inc For: 12 August By Investing.com - Investing.com India
Lexeo Therapeutics Inc Azioni (LXEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lexeo Therapeutics Inc Azioni (LXEO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Townsend Richard Nolan | Chief Executive Officer |
Aug 18 '26 |
Sale |
4.95 |
3,345 |
16,562 |
374,472 |
| Otero Jose Manuel | Chief Operating Officer |
Aug 18 '26 |
Sale |
4.96 |
1,304 |
6,464 |
136,178 |
| Townsend Richard Nolan | Officer |
Aug 18 '26 |
Proposed Sale |
4.95 |
3,345 |
16,562 |
0 |
| Otero Jose Manuel | Officer |
Aug 18 '26 |
Proposed Sale |
4.96 |
1,304 |
6,464 |
0 |
| Tamayo Louis Edward | Officer |
Aug 18 '26 |
Proposed Sale |
4.91 |
4,117 |
20,203 |
0 |
| Tamayo Louis Edward | Chief Financial Officer |
Jul 01 '26 |
Sale |
4.49 |
4,641 |
20,838 |
97,024 |
| Otero Jose Manuel | Chief Operating Officer |
Jul 01 '26 |
Sale |
4.48 |
4,666 |
20,904 |
137,482 |
| Bhalla Narinder Pal | Chief Medical Officer |
Jul 01 '26 |
Sale |
4.42 |
22,306 |
98,593 |
82,194 |
| Townsend Richard Nolan | Chief Executive Officer |
Jul 01 '26 |
Sale |
4.48 |
25,947 |
116,243 |
377,817 |
| Otero Jose Manuel | Officer |
Jul 01 '26 |
Proposed Sale |
4.48 |
4,666 |
20,919 |
0 |
4.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):